We subsequently provide evidence that upregulation of interferon response genes mediates this effect, and show that the clinically relevant HSP90 inhibitor ganetespib potentiates responses to anti-CTLA4 and anti-PD-1 immunotherapy in a preclinical murine tumor model. This evidence concerns the gene CTLA4 and neoplasm.